- Home
- CTHR vs OGEN Comparison
CTHR vs OGEN Comparison
Compare CTHR & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTHR
- OGEN
- Stock Information
- Founded
- CTHR 1995
- OGEN 1996
- Country
- CTHR United States
- OGEN United States
- Employees
- CTHR N/A
- OGEN N/A
- Industry
- CTHR Consumer Specialties
- OGEN Biotechnology: Pharmaceutical Preparations
- Sector
- CTHR Consumer Discretionary
- OGEN Health Care
- Exchange
- CTHR Nasdaq
- OGEN Nasdaq
- Market Cap
- CTHR 4.1M
- OGEN 3.9M
- IPO Year
- CTHR 1997
- OGEN N/A
- Fundamental
- Price
- CTHR $1.41
- OGEN $0.29
- Analyst Decision
- CTHR
- OGEN
- Analyst Count
- CTHR 0
- OGEN 0
- Target Price
- CTHR N/A
- OGEN N/A
- AVG Volume (30 Days)
- CTHR 10.5K
- OGEN 14.3M
- Earning Date
- CTHR 03-04-2025
- OGEN 03-28-2025
- Dividend Yield
- CTHR N/A
- OGEN N/A
- EPS Growth
- CTHR N/A
- OGEN N/A
- EPS
- CTHR N/A
- OGEN N/A
- Revenue
- CTHR $23,684,860.00
- OGEN N/A
- Revenue This Year
- CTHR $31.82
- OGEN N/A
- Revenue Next Year
- CTHR N/A
- OGEN N/A
- P/E Ratio
- CTHR N/A
- OGEN N/A
- Revenue Growth
- CTHR N/A
- OGEN N/A
- 52 Week Low
- CTHR $1.16
- OGEN $0.25
- 52 Week High
- CTHR $4.30
- OGEN $3.84
- Technical
- Relative Strength Index (RSI)
- CTHR 46.53
- OGEN 46.16
- Support Level
- CTHR $1.28
- OGEN $0.28
- Resistance Level
- CTHR $1.40
- OGEN $0.31
- Average True Range (ATR)
- CTHR 0.07
- OGEN 0.05
- MACD
- CTHR -0.01
- OGEN 0.00
- Stochastic Oscillator
- CTHR 54.17
- OGEN 9.39
About CTHR Charles & Colvard Ltd
Charles & Colvard Ltd manufactures, markets, and distributes finished jewellery which also includes moissanite gemstone in the jewellery market. The company sells jewels through two operating segments namely Online Channels segment and Traditional segment. It generates maximum revenue from the Online Channels segment. Online Channels segment which consists of e-commerce outlets including charlesandcolvard.com, moissaniteoutlet.com, third-party online marketplaces, drop-ship retail, and other pure-play, exclusively e-commerce outlets.
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification.